Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.57 |
| ▸ | IL1B | P01584 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | PLG | P00747 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199599 | 1.00 | CASP1 (0.57) | CASP1IL1BACEF2PLG | |
| SCHEMBL10202054 | 1.00 | CASP1 (0.57) | CASP1IL1BACEF2PLG | |
| SCHEMBL10199605 | 0.89 | CASP1 (0.71) | CASP1IL1BACEF2PLG | |
| SCHEMBL10201703 | 0.87 | CASP1 (0.45) | CASP1IL1BF2PLGPRSS1 | |
| SCHEMBL10247884 | 0.85 | CASP1 (0.80) | CASP1IL1BACELCK | |
| SCHEMBL10199344 | 0.85 | CASP1 (0.80) | CASP1IL1BACELCK | |
| SCHEMBL10199879 | 0.85 | CASP1 (0.63) | CASP1IL1BF2PLGLCK | |
| SCHEMBL10248162 | 0.85 | CASP1 (0.63) | CASP1IL1BF2PLGLCK | |
| SCHEMBL10199850 | 0.84 | CASP1 (0.64) | CASP1IL1BACEF2PLG | |
| SCHEMBL10247963 | 0.84 | CASP1 (0.64) | CASP1IL1BACEF2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885IL1B 3/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.